Extracellular Vesicles-Based Additive for IVF Culture Media to Improve Fertility Treatment Success Rates

EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

EXP02 is a trace-add MSC-EV supplement for standard IVF culture media—clinics simply add a small amount with no workflow change. It is designed to increase the rate of good blastocysts and thereby reduce cycles and cost per live birth. The addressable market is ~3M IVF cycles worldwide and ~0.5M in Japan, with demand expected to rise as childbearing shifts later.

In preclinical models, EXP02 improved the efficiency of development to the blastocyst stage, increased the proportion of good-quality embryos in advanced-age mice, and improved hatching, demonstrating both quantitative and qualitative benefits that support clinical adoption.

Progress includes a NEDO grant awarded in Japan, three conference presentations, efficacy confirmed, and identification of key components, with a JP patent application filed. Built on Prime-EV with QC markers and Advanced CMC that enables high-accuracy potency prediction and lot-to-lot consistency across >1,000 lots, the program is set for CDMO-partnered scale-up and a Japan-first, then global rollout combining direct sales and distributors.